Format

Send to

Choose Destination
J Acquir Immune Defic Syndr. 2019 Dec 1;82 Suppl 2:S148-S154. doi: 10.1097/QAI.0000000000002176.

Using Interrupted Time Series Analysis to Measure the Impact of Legalized Syringe Exchange on HIV Diagnoses in Baltimore and Philadelphia.

Author information

1
Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington University, Washington, DC.
2
Department of Sociology, Center for Health, Risk, and Society, American University, Washington, DC.
3
Department of Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
4
Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
5
Treatment Research Institute, Philadelphia, PA.
6
Prevention Point Philadelphia, Philadelphia, PA.
7
AIDS Activities Coordinating Office, Philadelphia Department of Public Health, Philadelphia, PA.
8
Bureau of HIV/STD Services, Baltimore City Health Department, Baltimore, MD.
9
Office of the Commissioner, Baltimore City Health Department, Baltimore, MD.

Abstract

BACKGROUND:

Syringe exchange programs (SEP) reduce HIV incidence associated with injection drug use (IDU), but legislation often prohibits implementation. We examined the policy change impact allowing for SEP implementation on HIV diagnoses among people who inject drugs in 2 US cities.

SETTING:

Philadelphia, PA, and Baltimore, MD.

METHODS:

Using surveillance data from Philadelphia (1984-2015) and Baltimore (1985-2013) for IDU-associated HIV diagnoses, we used autoregressive integrated moving averages modeling to conduct 2 tests to measure policy change impact. We forecast the number of expected HIV diagnoses per city had policy not changed in the 10 years after implementation and compared it with the number of observed diagnoses postpolicy change, obtaining an estimate for averted HIV diagnoses. We then used interrupted time series analysis to assess the immediate step and trajectory impact of policy change implementation on IDU-attributable HIV diagnoses.

RESULTS:

The Philadelphia (1993-2002) model predicted 15,248 new IDU-associated HIV diagnoses versus 4656 observed diagnoses, yielding 10,592 averted HIV diagnoses over 10 years. The Baltimore model (1995-2004) predicted 7263 IDU-associated HIV diagnoses versus 5372 observed diagnoses, yielding 1891 averted HIV diagnoses over 10 years. Considering program expenses and conservative estimates of public sector savings, the 1-year return on investment in SEPs remains high: $243.4 M (Philadelphia) and $62.4 M (Baltimore).

CONCLUSIONS:

Policy change is an effective structural intervention with substantial public health and societal benefits, including reduced HIV diagnoses among people who inject drugs and significant cost savings to publicly funded HIV care.

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center